432001-69-9
432001-69-9
Chemical Structure
Skp2 Inhibitor C1
Synonym(s): SKPin C1
- CAS No.: 432001-69-9
- Formula:C18H13BrN2O4S2
- Molecular Weight:465.34
IUPAC Name: (Z)-2-(4-bromo-2-((4-oxo-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-5-ylidene)methyl)phenoxy)acetic acid
InChIKey: IYCJJVVXEHZJHE-CHHVJCJISA-N
SMILES: S=C(S/1)N(CC2=CN=CC=C2)C(C1=C\C(C=C(Br)C=C3)=C3OCC(O)=O)=O
Biological Activity: Skp2 Inhibitor C1 (SKPin C1) is an S-phase kinase-related protein 2 (Skp2) inhibitor with an inhibitory effect on metastatic melanoma cells. Skp2 Inhibitor C1 slows the cell cycle, inhibits cell proliferation, and triggers apoptosis[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Skp2 Inhibitor C1 | 98.05% | Skp2 Inhibitor C1 (SKPin C1) is an S-phase kinase-related protein 2 (Skp2) inhibitor with an inhibitory effect on metastatic melanoma cells. Skp2 Inhibitor C1 slows the cell cycle, inhibits cell proliferation, and triggers apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
4E2RCat | 98.0% | 4E2RCat is an inhibitor of eIF4E-eIF4G interaction with an IC50 of 13.5 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CY-09 (Standard) | ≥98% | CY-09 (Standard) is the analytical standard of CY-09 (HY-103666). This product is intended for research and analytical applications. CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GQ-16 | 98.12% | GQ-16 is an orally active PPARγ partial agonist with an IC50 of 1.84 μM and a Ki of 160 nM against human PPARγ. GQ-16 inhibits Cdk5-mediated Ser-273 phosphorylation. GQ-16 improves insulin sensitivity and glucose tolerance in obese and diabetic mice. GQ-16 also exhibits certain cytotoxicity against tumor cells. GQ-16 can be used in research related to obesity, diabetes and cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PRL-3 Inhibitor I | 98.11% | PRL-3 Inhibitor I is a potent PRL-3 inhibitor with an IC50 of 0.9 μM. PRL-3 Inhibitor I shows a reduced invasion in cell-based assay. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
WAY-620445 | ≥95.0% | WAY-620445 is an active molecule. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ASK1-IN-4 | ASK1-IN-4 is an ASK1 inhibitor (IC50 = 0.2 μM) that interacts with the ATP binding site of ASK1. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(E/Z)-ASK1-IN-4 | 98.03% | (E/Z)-ASK1-IN-4 is an isomer of ASK1-IN-4 (HY-153761). ASK1-IN-4 is an ASK1 inhibitor (IC50 = 0.2 μM) that interacts with the ATP binding site of ASK1. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Leukadherin-1 | 98.0% | Leukadherin-1, a specific agonist of the leukocyte surface integrin CD11b/CD18, increases CD11b/CD18-dependent cell adhesion to fibrinogen with an EC50 of 4 μM. Leukadherin-1 enhances leukocyte adhesion to ligands (such as ICAM-1) and vascular endothelium and thus reduces leukocyte transendothelial migration and influx to the injury sites. Leukadherin-1 suppresses innate inflammatory signaling. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PPARγ agonist 10 | PPARγ agonist 10 (compound 33g) is a PPARγ agonist, and stimulats the insulin secretion, glucose uptake and insulin Sensitivity in βTC6 Cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pin1 modulator 1 | 96.26% | Pin1 modulator 1 (compound IIb-219) is a modulator that specifically targets β-Catenin and inhibits the Wnt pathway. Pin1 modulator 1 can be used in the study of Wnt-mediated related diseases, such as cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
